The key facts
- The 2026–2031 master plan was approved by Sheikh Khaled bin Mohamed at a meeting of the Emirates Genome Council
- The Emirati Genome programme has reached 1 million participants; the plan envisages covering 100% of UAE citizens
- Personalised reports on 214 hereditary conditions — via the Tamm platform from December 2026
Approval of the master plan
The Crown Prince of Abu Dhabi and Chairman of the emirate's Executive Council, Sheikh Khaled bin Mohamed, has approved the National Genomics Master Plan for 2026–2031. The approval took place at a meeting of the Emirates Genome Council held on the sidelines of the UAE Government Annual Meetings, reports The National.
From data collection to the clinic
The plan marks a strategic shift from accumulating genomic data to applying it in clinical practice, early prevention and precision medicine. Its foundation is the one-million-participant milestone reached by the Emirati Genome programme, which, according to officials, makes it the largest population genomics programme in the world. The master plan includes four initiatives: extending the programme to 100% of UAE citizens, providing personalised genomic reports to 900,000 participants, expanding newborn genetic screening nationwide, and strengthening the Trusted Research Environment — a secure digital environment for AI-driven data analysis, which since launch has received invitations from 21 research and medical organisations from various countries.
What participants will receive and when
Personalised genomic reports will be issued through the Tamm platform starting December 2026 and will cover 214 hereditary genomic conditions and health traits. The newborn screening programme covers more than 730 genes linked to over 815 childhood genetic conditions for which early treatment is available. Mansour Al Mansouri, Chairman of the Abu Dhabi Department of Health and Secretary General of the Emirates Genome Council, said the master plan 'sets new benchmarks for implementing genomics in community-level clinical applications,' and that the genomic database combined with an AI-based healthcare system will enable a shift to prevention and precision medicine across society.
Context of earlier results
Earlier, in February 2026, the same outlet reported a scientific result based on the programme's data: The Emirati Genome Programme has enabled progress in the study of inherited vision loss. This illustrates the direction the master plan now consolidates institutionally — moving from research on accumulated data to the systematic clinical application of genomic information for citizens.
